In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models
These findings demonstrate that myeloid cells can be directly engineered <i>in vivo</i> to kill tumor cells and orchestrate an adaptive immune response and guide clinical studies for the treatment of solid tumors.
Authors
- Hongyun Zhao (ORCID: https://orcid.org/0000-0002-1251-3888)
- Michael Gorgievski
- Josephine D’Alessandro
- Bruce McCreedy
- Neha Diwanji (ORCID: https://orcid.org/0000-0001-9828-5793)
- Daniel R. Getts (ORCID: https://orcid.org/0000-0002-5555-9659)
- Shannon Argueta
- Ewa Grudzien‐Nogalska
- Jian Ding (ORCID: https://orcid.org/0000-0003-1525-5332)
- Yuxiao Wang (ORCID: https://orcid.org/0000-0002-9505-679X)
- Thomas Prod’homme
- Edward L. Cochran
- Robert Hofmeister
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-13
- DOI
- https://doi.org/10.3389/fimmu.2024.1501365
- Citations
- 12
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.39